Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 467

Sort by

Sort Order Select

Journal Articles

DARTs point the way forward in AML

Saar Gill

Blood (2021) 137 (6): 720–721.

https://doi.org/10.1182/blood.2020009020

Published: 2021

Journal Articles

Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy

Wilhelm Woessmann, Martin Zimmermann, Andrea Meinhardt, Stephanie Müller, Holger Hauch, Fabian Knörr, Ilske Oschlies, Wolfram Klapper, Felix Niggli, Edita Kabickova, Andishe Attarbaschi, Alfred Reiter, Birgit Burkhardt

Blood (2020) 135 (14): 1124–1132.

https://doi.org/10.1182/blood.2019003591

Published: 2020

Includes: Supplemental data

Journal Articles

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

Johann K. Hitzler, MD, Jason Berman, MD, Robert B. Gerbing, Amy Beckman, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Todd E Druley, MD PhD, Michael R. Loken, PhD, Lisa Eidenschink Brodersen, PhD, Karen Chisholm, Shelton A. Viola, MD, Jeffrey W. Taub, MD, Alan S Gamis, MD MPH, Todd A. Alonzo, PhD, E. Anders Kolb, MD

Blood (2019) 134 (Supplement_1): 118.

https://doi.org/10.1182/blood-2019-126723

Published: 2019

Journal Articles

EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab

Frits van Rhee, MD PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Jeffery R. Sawyer, Adam Rosenthal, MS, Doug Steward, Phil Farmer, Robert Smith, Milan Bimali, PhD, Mariam M. Boota, MD, Clyde Bailey, Brian A Walker, PhD, Antje Hoering, PhD, Gareth Morgan, MD PhD, Maurizio Zangari, MD, Faith E. Davies, MD

Blood (2019) 134 (Supplement_1): 4569.

https://doi.org/10.1182/blood-2019-131887

Published: 2019

Journal Articles

Development of Target Modules for Early and Late Stage Cancer Treatment Using Switchable Unicar T Cell Therapy

Liliana Raquel Loureiro, PhD, Anja Feldmann, PhD, Ralf Bergmann, PhD, Nicole Berndt, PhD, Stefanie Koristka, PhD, Nicola Mitwasi, Anja Hoffmann, Justyna Jureczek, Martin Bornhaeuser, MD, Michael Bachmann, MD, Claudia Arndt, PhD

Blood (2019) 134 (Supplement_1): 5613.

https://doi.org/10.1182/blood-2019-128249

Published: 2019

Journal Articles

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Michela Ansuinelli, MD, Antonella Vitale, MD, Giovanna Pecoraro, MD, Saveria Capria, MD, Silvia Maria Trisolini, MD, Clara Minotti, MD, Claudio Cartoni, MD, Anna Maria Testi, MD, Maria Luisa Moleti, MD, Anna Paola Iori, MD, Walter Barberi, MD PhD, Irene Della Starza, PhD, Loredana Elia, Bs, Francesca Mancini, Maria Stefania De Propris, Anna Guarini, PhD, Sabina Chiaretti, MD PhD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 5121.

https://doi.org/10.1182/blood-2019-128156

Published: 2019

Journal Articles

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Yukio Kobayashi, Iekuni Oh, MD PhD, Toshihiro Miyamoto, MD PhD, Won-Sik Lee, Hiroatsu Iida, MD PhD, Hironobu Minami, MD PhD, Yoshinobu Maeda, MD PhD, Jun Ho Jang, Sung-Soo Yoon, MD PhD, Su-Peng Yeh, MD, Qui Tran, Joan Morris, Janet L. Franklin, Ka-Wing Chong, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 5069.

https://doi.org/10.1182/blood-2019-124582

Published: 2019

Journal Articles

Cost Effective Cardio Protective Intervention in Haploidentical Hematopoietic Stem Cell Transplantation in Children - a Study from a Tertiary Care Centre in India

Revathi Raj, Ramya Uppuluri, MD, Venkateswaran Vellaichamy, MD, Nikila Ravichandran, MD, Kesavan Melarkode Ramanan, MD

Blood (2019) 134 (Supplement_1): 5866.

https://doi.org/10.1182/blood-2019-131539

Published: 2019

Journal Articles

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Eric Huselton, MD, Amanda F Cashen, MD, John F. DiPersio, MD PhD, Meagan Jacoby, MD, Iskra Pusic, MD, Rizwan Romee, MD PhD, Mark A. Schroeder, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD

Blood (2019) 134 (Supplement_1): 3915.

https://doi.org/10.1182/blood-2019-132065

Published: 2019

Journal Articles

Super factor Va, an Engineered Factor V Molecule, Effectively Reduces Bleeding and Acute Coagulopathy in Mouse Models of Trauma and Shock

Bilgimol Chumappumkal Joseph, PhD, Laurent O Mosnier, Annette von Drygalski, MD PharmD

Blood (2019) 134 (Supplement_1): 1101.

https://doi.org/10.1182/blood-2019-124433

Published: 2019

Journal Articles

Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO)

Franco Locatelli, MD, Gerhard Zugmaier, Peter Bader, MD, Sima Jeha, MD, Paul-Gerhardt Schlegel, Jean-Pierre Bourquin, MD PhD, Rupert Handgretinger, MD, Benoit Brethon, MD, Claudia Rossig, Christiane Chen-Santel

Blood (2019) 134 (Supplement_1): 1294.

https://doi.org/10.1182/blood-2019-121615

Published: 2019

Journal Articles

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Deborah A. Katz, MD, Michael P. Chu, Kevin A. David, MD, Catherine Thieblemont, MD PhD, Nicholas J. Morley, Sharif S. Khan, Yuqi Chen, James Kalabus, Joan Morris, Abraham Anderson, Ariel A. Avilion, Eva González-Barca, MD PhD

Blood (2019) 134 (Supplement_1): 4077.

https://doi.org/10.1182/blood-2019-121708

Published: 2019

Journal Articles

Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis

Janny M. Yao, PharmD, Dongyun Yang, PhD, Saloomeh Mokhtari, Amandeep Salhotra, MD, Haris Ali, MD, Shukaib Arslan, MD, Salman Otoukesh, MD, Ibrahim Aldoss, MD, Karamjeet S. Sandhu, MD, Anthony Stein, MD, David Snyder, MD, Vinod A. Pullarkat, MD, Guido Marcucci, MD, Stephen J Forman, MD, Ryotaro Nakamura, MD, Monzr M. Al Malki, MD

Blood (2019) 134 (Supplement_1): 4518.

https://doi.org/10.1182/blood-2019-129221

Published: 2019

Journal Articles

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Hsu, RN, Clare Sun, MD, Adrian Wiestner, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 3052.

https://doi.org/10.1182/blood-2019-130807

Published: 2019

Journal Articles

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

Blood (2019) 134 (Supplement_1): 3919.

https://doi.org/10.1182/blood-2019-130635

Published: 2019

Journal Articles

The Efficacy and Safety of Cladribine in Combination with Cytarabine ,ATRA, G-CSF and Mitoxantrone(Claag-M Regimen)in Relapsed/Refractory AML : A Phase 1/2, Prospective, Single-Arm, Multicenter Study

Tinghua Zhang, Yinghua Xie, Limin Zhao, Xiyao Han, Yingting Lu, Jing Zhang, Yanhui Xie, Qi Zhu, Lihua Sun, Li Yang, Ligen Liu

Blood (2019) 134 (Supplement_1): 3843.

https://doi.org/10.1182/blood-2019-125739

Published: 2019

Journal Articles

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Maria Calbacho, MD, Jordi Sierra Gil, MD PhD, Jaime Perez De Oteyza, MD PhD, Jacob M. Rowe, MB, BS, Ofir Wolach, MD, Yishai Ofran, MD, Yakir Moshe, MD, Jichao Sun, PhD, Jan Baughman, MPH, Eileen McNulty, MS, Ezio Bonvini, MD, Jon M. Wigginton, MD, Jan K Davidson-Moncada, MD PhD

Blood (2019) 134 (Supplement_1): 2662.

https://doi.org/10.1182/blood-2019-125966

Published: 2019

Journal Articles

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Blood (2019) 134 (Supplement_1): 733.

https://doi.org/10.1182/blood-2019-122073

Published: 2019

Journal Articles

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, MD, Paul Frankel, PhD, Christopher Ruel, Mehrdad Abedi, MD, Emily Schwab, BS, Caitlin L. Costello, MD, Jasmine Zain, MD, Lihua E Budde, MD PhD, Basem M. William, MRCP,MD, Francine M. Foss, MD, Brian A Jonas, MD PhD, Aaron Seth Rosenberg, MD, Edward Newman, PhD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 760.

https://doi.org/10.1182/blood-2019-124254

Published: 2019

Journal Articles

High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3

Bhaskar Kolla, MBBS, Nurul Aidah Abdul Halim, MBBS, Zohar Sachs, MD PhD, Erica D. Warlick, MD, Daniel J. Weisdorf, MD, Fiona He, MD, Lao Zhentang, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 3432.

https://doi.org/10.1182/blood-2019-123306

Published: 2019

NARROW

DARTs point the way forward in AML

Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction

EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab

Development of Target Modules for Early and Late Stage Cancer Treatment Using Switchable Unicar T Cell Therapy

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Cost Effective Cardio Protective Intervention in Haploidentical Hematopoietic Stem Cell Transplantation in Children - a Study from a Tertiary Care Centre in India

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Super factor Va, an Engineered Factor V Molecule, Effectively Reduces Bleeding and Acute Coagulopathy in Mouse Models of Trauma and Shock

Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO)

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

The Efficacy and Safety of Cladribine in Combination with Cytarabine ,ATRA, G-CSF and Mitoxantrone(Claag-M Regimen)in Relapsed/Refractory AML : A Phase 1/2, Prospective, Single-Arm, Multicenter Study

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only